David J. Leaver

Dr. David J. Leaver

School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Nature
Verified
Journal Article
Closed access
PDF file
JBJonathan Bayldon Baell
Jonathan Bayldon Baell
David J. LeaverDavid J. Leaver
David J. Leaver
SHStefan J. Hermans
Stefan J. Hermans
GKGemma L. Kelly
Gemma L. Kelly
MBMargs S. Brennan
Margs S. Brennan
TTTim Thomas
Tim Thomas

1 February 2015 in Cell Metabolism
Verified
Journal Article
Closed access
FSFabio Rinaldo Santori
Fabio Rinaldo Santori
PHPengxiang Huang
Pengxiang Huang
SPSerge A. van de Pavert
Serge A. van de Pavert
EDEugene F. Douglass
Eugene F. Douglass
David J. LeaverDavid J. Leaver
David J. Leaver
DLDan R. Littman
Dan R. Littman

11 December 2019 in Nature
Verified
Journal Article
Closed access
LMLaura MacPherson
Laura MacPherson
JAJuliana Anokye
Juliana Anokye
MYMiriam M. Yeung
Miriam M. Yeung
ELEnid Y. N. Lam
Enid Y. N. Lam
YCYih-Chih Chan
Yih-Chih Chan
MDMark A. Dawson
Mark A. Dawson

29 June 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
David J. LeaverDavid J. Leaver
David J. Leaver
BCBenjamin Cleary
Benjamin Cleary
NNNghi Tiger-Eye Nguyen
Nghi Tiger-Eye Nguyen
DPDaniel L. Priebbenow
Daniel L. Priebbenow
HLH. Rachel Lagiakos
H. Rachel Lagiakos
JBJonathan Bayldon Baell
Jonathan Bayldon Baell

2 March 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DPDaniel L. Priebbenow
Daniel L. Priebbenow
David J. LeaverDavid J. Leaver
David J. Leaver
NNNghi Nguyen
Nghi Nguyen
BCBenjamin Cleary
Benjamin Cleary
HLH. Rachel Lagiakos
H. Rachel Lagiakos
JBJonathan Bayldon Baell
Jonathan Bayldon Baell

17 July 2018 in Molecules
Verified
Journal Article
Open access
PDF file
David J. LeaverDavid J. Leaver
David J. Leaver
Sterol 14α-demethylase (SDM) is essential for sterol biosynthesis and is the primary molecular target for clinical and agricultural antifungals. SDM has been demonstrated to be a valid drug target for antiprotozoal therapies, and much research has been focused on using SDM inhibitors to treat neglected tropical diseases such as human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis. Sterol C24-methyltransferase (24-SMT) introduces the C24-methyl group of ergosterol and is an enzyme found in pathogenic fungi and protozoa but is absent from animals. This difference in sterol metabolism has the potential to be exploited in the development of selective drugs that specifically target 24-SMT of invasive fungi or protozoa without adversely affecting the human or animal host. The synthesis and biological activity of SDM and 24-SMT inhibitors are reviewed herein.